

Bioteknik och läkemedelAgencourt Bioscience Corporation Agencourt Bioscience Corporation provides genomics services and nucleic acid purification reagents to biotech and pharmaceutical companies, academic institutions and government facilities. Its Discovery Solutions suite of services span genomic, functional genomic and proteomic fields that aid biotechnology and pharmaceutical companies improve the efficiency of their drug discovery pipelines. Agencourt’s GLP-compliant facility is located in Beverly, Mass., and is online at www.agencourt.com.
Agencourt was started in July 2000 offering nucleic acid purification reagents based on its patented Solid Phase Reversible Immobilization (SPRI™) technology. Agencourt’s co-chief scientific officers were involved in the development of SPRI technology at the Whitehead Institute as part of the Human Genome Project. Agencourt quickly expanded to offer a suite of sequencing services based on SPRI nucleic acid purification technology. SPRI purification technology was used to sequence over a third of the human genome and has been adopted by many of the top genomic centers. Most recently, Agencourt was recognized as a leading sequencing center by the NIH and will participate in the sequencing of genomes of organisms identified as having biomedical importance.
HTG High Throughput Genomics, Inc., (HTG), is a provider of transcriptomic technology and services. HTG’s technology opens a new era of drug discovery and allows companies to identify new drug compounds, quickly eliminate less promising compounds and bring new drugs to market faster. HTG is the first company to commercialize this technology. HTG is online at www.htgenomics.com.
|